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have achieved Food and Drug Administration (FDA) and European
Medicines Agency (EMA) regulatory approval and even European reim-
bursement approval where no therapeutic alternative exists and early-
stage data indicate dramatic clinical beneﬁts. Objective: This research
aimed to compare under what circumstances oncologics can obtain
both regulatory and reimbursement approval in Australia on this basis.
Methods: Therapeutic Goods Administration (TGA) Australian Public
Assessment Reports, EMA, FDA, and Pharmaceutical Beneﬁts Advisory
Committee (PBAC) Public Summary Documents were extracted for any
oncologic indication appraised in Australia on a pivotal trial package
lacking phase III data, excluding pediatric indications and new formu-
lations. Results: Australian Public Assessment Reports were available
for six TGA-appraised oncologics across seven indications on such a
data package: ﬁve of seven approved, one of seven restricted, and one of
seven rejected. The EMA and the FDA issued recommendations on
these indications an average of 1 and 2 years earlier, respectively. The
PBAC appraised six oncologics across 10 indications on such a dataee front matter Copyright & 2015, International S
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K.package, with four (nilotinib, dasatinib, imatinib, and brentuximab
vedotin) approved and two rejected (cetuximab and bevacizumab).
Seven of the eight approved indications required multiple submissions,
with inadequate clinical data frequently cited as key. Six of the eight
PBAC-approved indications included economic modeling on a cost-
beneﬁt approach. Conclusions: The TGA will approve oncologics that
offer potentially substantial clinical beneﬁts on the basis of an indirect
comparison of single-arm trials but at a delay versus the EMA and the
FDA. The PBAC reimbursement approval also requires more rigorous
supportive clinical data and acceptable cost-effectiveness as demon-
strated on a cost-beneﬁt or cost-quality-adjusted life-year metric.
Keywords: oncology drugs, Australia, regulatory approval,
reimbursement approval, expedited assessment.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
A drug will be granted a license to be sold in a speciﬁc jurisdiction
once it receives approval from the relevant regulatory body that
assesses its quality, efﬁcacy, and safety. Regulatory bodies
include the Therapeutic Goods Administration (TGA) for Aus-
tralia, the European Medicines Agency (EMA) for Europe, and the
Food and Drug Administration (FDA) for the United States. Such
regulatory approval typically requires data from a phase III
randomized controlled trial (RCT) that often comprises several
hundred patients and spans many years. Such a trial is necessary
to demonstrate the comparative efﬁcacy and safety of the new
drug. This is the key ﬁnal step of a process from drug discovery to
regulatory approval that typically requires 10 to 15 years, the cost
of which has been estimated at more than US $1 billion per
approved drug [1].There are issues, however, with requiring phase III trial data
before granting approval for some conditions. For diseases with
small patient populations, the potential market size may be
insufﬁcient to justify the substantial development costs. Indeed,
for very rare diseases, there may not be even enough patients to
conduct such a phase III trial. For severely life-threatening
diseases with few or no effective treatment options, there may
be drugs that already indicate transformational clinical beneﬁt in
early-stage single-arm phase I or II trials. Denying patients access
to such therapies until phase III trials have been completed raises
serious ethical issues. Thus, there is a demand and need for
certain drugs to receive regulatory approval earlier in the devel-
opmental pathway, without delaying access until supportive
comparative phase III data are available.
Both the EMA and FDA regulatory bodies have several well-
established expedited registrational programs available forociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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need (typically cancers). These programs allow patients earlier
access in their developmental pathway through expedited
assessment as well as access on a less mature data package
conditional on the sponsor conducting further studies to validate
the degree of clinical beneﬁt. Thus, the EMA will grant acceler-
ated approval and conditional approval [2], whereas the FDA has
an accelerated-approval program as well as fast-track designa-
tion and priority reviews [3]. Indeed, previous research has
demonstrated that the FDA has approved 28 oncologics across
37 indications [4] and the EMA 15 oncologics across 24 indications
on the basis of data packages in which the pivotal trial was not a
comparative phase III study (excluding pediatric indications or
new formulations, which are well recognized as not requiring a
full phase III data package for market access) [5]. Interestingly, in
Europe, the clinical data packages that led to EMA approval for a
number of these treatments contributed to the receipt of favor-
able pricing and reimbursement status by key European health
technology assessment (HTA) bodies [6].
Recent reforms by these regulatory bodies will enable yet
more drugs to gain regulatory approval at potentially even earlier
points in their developmental pathway. Since January 2013, FDA
breakthrough status has given drugs for severe diseases expe-
dited review where preliminary clinical evidence demonstrates
substantial improvement over existing therapies [3]. Indeed,
under this pathway two drugs have been approved on a data
package supported by phase I data alone (ceritinib in non–small
cell lung carcinoma [April 2014] and pembrolizumab in mela-
noma [September 2014] [7,8]). In April 2014, the EMA announced
an adaptive reimbursement pilot program, a new paradigm in
regulatory approval in which initial access to patients with very
severe unmet need will be granted on very early-stage data; as
more mature data become available, the patient population will
be expanded [9].
The Australian regulatory body, the TGA, has no such expe-
dited registrational programs for treatments of severe conditions
that lack effective alternatives. Furthermore, once regulatory
approval has been granted, additional delays are often encoun-
tered when the drug seeks public reimbursement through the
Australian HTA body: The Pharmaceutical Beneﬁts Advisory
Committee (PBAC). The PBAC appraises drugs on the basis of
their clinical and cost-effectiveness, and often requires drugs to
be submitted multiple times to achieve reimbursement [10]. The
entire process in Australia, from initial application to the TGA toTable 1 – Comparing outcomes and dates of oncologic dr
data package lacking comparative phase III data to those
Drug Indication T
Bevacizumab Glioblastoma Dec
Brentuximab sALCL May
Brentuximab HL May
Crizotinib§ NSCLC Sep
Ofatumumab CLL Dec
Pralatrexate PTCL Aug
Vismodegib BCC Sep
BCC, basal cell carcinoma; CLL, chronic lymphocytic leukemia; EMA, Eur
Hodgkin lymphoma; NSCLC, non–small cell lung carcinoma; PTCL, p
lymphoma; TGA, Therapeutic Goods Administration.
* Approved.
† Not appraised/not publicly available.
‡ Restricted approval.
§ Crizotinib was approved by the TGA only after an interim study repor
with just topline study results from the phase III study and the FDA a
|| Not approved.gaining listing on the Pharmaceutical Beneﬁts Scheme (PBS) and
achieving complete public reimbursement, took an average of
31.0 months in 2013 [11]. This has resulted in delayed access for
oncology medicines in Australia to a greater extent than in other
developed markets [11]. This issue is particularly pertinent in
Australia, given that it has the highest age-standardized inci-
dence of cancer in the world [12].
This research aimed to deﬁne the conditions under which
drugs lacking phase III supportive trial data could achieve both
TGA regulatory approval and public reimbursement through
PBAC approval and PBS listing.Methods
All publicly available TGA Australian Public Assessment Reports
(AusPARs) [13] and PBAC Public Summary Documents [14] up to
October 1, 2014, were screened to determine on what level of
supportive clinical trial evidence each submission was based. A total
of 472 AusPARs and 438 Public Summary Documents were screened.
Any appraisal for an oncology drug for which the main clinical study
was not a comparative phase III trial was extracted. Pediatric
indications and new formulations, which are well recognized as
being approved on a less than fully comprehensive phase III trial
data package, were excluded from this analysis. For the six AusPARs
(covering a total of seven indications) and six Public Summary
Documents (covering a total of nine indications) that were appraised
on such a data package, the TGA and PBAC date, decision, trial
package, and key rationale were extracted. Furthermore, any publicly
available corresponding EMA European Public Assessment Reports
[15] and FDA decision summaries [16] for these TGA-approved
indications were extracted. The appraisal outcomes, dates, and key
rational were then compared to provide perspectives on how
TGA-approved therapies on data packages lacking comparative
phase III data have been appraised by other major regulatory bodies.Results
Starting with regulatory decisions, AusPARs were available for six
oncologic drugs across seven indications on the basis of a data
package lacking comparative phase III data (Table 1). Four of
seven of these indications received full TGA approval and one of
seven had received restricted approval, whereas one of seven wasug appraisals by the TGA on the basis of pivotal trial
of the EMA and the FDA.
GA EMA FDA
2009* † May 2009*
2014* Oct 2012* Aug 2011*
2014‡ Oct 2012‡ Aug 2011*
2013* Oct 2012* Aug 2011*
2010* Apr 2010‡ Oct 2009*
2013|| Apr 2012|| Sep 2009*
2013* Jul 2013* Jan 2012*
opean Medicines Agency; FDA, Food and Drugs Administration; HL,
eripheral T-cell lymphoma; sALCL, systemic anaplastic large cell
t of phase III data was made available (the EMA approved crizotinib
pproved on phase II data).
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after an interim study report of a comparative phase III trial was
made available.
TGA appraisals of oncology agents lacking comparative phase
III data frequently made reference to the EMA guidelines on the
Evaluation of Anticancer Medicinal Products in Man (EMEA/EWP/
205/95 Rev 3 Corr). These guidelines have been adopted by the TGA
and generally require provision of phase III data (comparing the
drug to an established comparator) to obtain marketing approval.
The submissions often note, however, that the TGA has previously
approved oncology applications on the basis of phase II data
in situations in which the evidence for efﬁcacy is convincing and
either 1) the condition is rare or 2) the condition is a life-
threatening one for which no other therapy is available. Indeed,
the TGA note that for several of these submissions the primary
end point is the overall response rate, which is not endorsed as a
primary end point in this TGA-adopted EMA guidance. If these
single-arm trials demonstrated sufﬁcient follow-up to include
survival end points, which indicated beneﬁt over historical con-
trols, however, this was considered acceptable. In the rejection
case of pralatrexate, time-to-progression data were presented in
addition to the primary end point overall response rate; patient
time-to-progression comparisons are endorsed by the TGA-
adopted EMA guidelines. Comparisons of time to progression,
however, were not clearly prespeciﬁed, and did not universally
favor pralatrexate, resulting in the rejection of this oncologic.
Publicly available EMA reports were available for six of the
seven TGA-appraised indications with highly congruent out-
comes (Table 1). Both the EMA and the TGA refused pralatrexate,
both similarly restricted brentuximab in Hodgkin lymphoma, and
both granted approval to brentuximab in systemic anaplastic
large cell lymphoma, crizotinib in non–small cell lung carcinoma,
and vismodegib in basal cell carcinoma. The only difference
between the EMA and the TGA in terms of outcomes was that
ofatumumab received restricted EMA approval but full TGA
approval. Nevertheless, the wording of the ﬁnal indications
approved by the EMA and the TGA were highly aligned. The
major difference was in the time taken to reach a decision, with
the EMA issuing its ﬁnal recommendations at an earlier time
point than did the TGA for all the six indications by an average of
almost 1 year (range 2–15 months; median 11.5 months, mean
11.8 months). In turn, the FDA issued its recommendationsFig. 1 – Timeline of oncology appraisals by the PBAC on the basis
data. ALL, acute lymphoblastic leukemia; ASM, aggressive syste
colorectal cancer; DMSP, dermatoﬁbrosarcoma protuberans; GBM
chronic eosinophilic leukemia; LYG, life-year gained; PBAC, Pha
myelodysplastic/myeloproliferative diseases; sALCL, systemic aconsistently earlier than did both the EMA and the TGA. Com-
pared with the TGA, the FDA supplied recommendations an
average of approximately 2 years before the TGA (range 7–47
months; median 25 months; mean 23.2 months). Furthermore,
the FDA approved all the seven indications without restrictions.
Moving onto reimbursement decisions, the PBAC has
appraised six oncologics across 10 indications on the basis of
noncomparative phase III data (Fig. 1). Six of the 10 indications
received approval without restrictions on this basis, 2 of the 10
indications received restricted approval, and 2 of the 10 indica-
tions were rejected by the PBAC. It is noteworthy that only a
proportion of AusPARs were made publicly available; therefore,
several drugs that were appraised by the PBAC on the basis of
data packages lacking comparative phase III data did not have a
corresponding AusPAR.
Six of the indications were appraised by the PBAC on the basis
of noncomparative phase II data, with 4 of 10 supported by case-
series data (Table 2). The magnitude of supportive data alone did
not appear to be correlated with the probability of drugs being
accepted; four of four indications were approved without restric-
tions on the basis of case-series data versus one of three
approved with more than one supportive phase II trial. Nine of
10 indications (all except cetuximab, which was rejected) were
recognized by the TGA as being orphan indications, with the 4
indications approved on case-series data also being recognized by
the PBAC as extremely rare disease subsets.
The PBAC deemed that all the 10 indications had relevant
active comparators and all submissions presented historical
control data versus these comparators against which economic
modeling was undertaken (Table 3). Only 3 of the 10 indications
presented an economic evaluation based on a quality-adjusted
life-year metric (only 1 of 3 was approved by the PBAC). Two of 10
presented cost/life-year gained data, and 4 of 10 presented cost/
responder analyses (those with case-series submissions), with 1
of 10 evaluated on a cost-minimization basis. All the ﬁve
indications with a PBAC-accepted incremental cost-
effectiveness ratio whose range fell below AU $75,000 were
approved, and only one above this threshold was approved
(dasatinib in acute lymphoblastic leukemia), the only indication
in which the PBAC accepted that the “Rule of Rescue” applied.
The Rule of Rescue enables more favorable cost-effectiveness
evaluation of any medicine that fulﬁls all the criteria: noof a pivotal trial data package lacking comparative phase III
mic mastocytosis; CML, chronic myeloid leukemia; CRC,
, glioblastoma; HES-CEL, hypereosinophilic syndrome-
rmaceutical Beneﬁts Advisory Committee; MDS/MPD,
naplastic large cell lymphoma.
Table 2 – The supportive clinical trial data package of oncologics appraised by the PBAC on the basis of a pivotal
trial data package lacking comparative phase III data.
Oncologic Indication Supportive trial data Number of trial patients
Imatinib ALL 5 phase II trials 528
Nilotinib CML 3 phase II trials 376
Bevacizumab GBM 2 phase II trials 215
Cetuximab DFSP 1 phase II trial 218
Brentuximab sALCL 1 phase II trial 58
Dasatinib ALL 1 phase II trial 26
Imatinib ASM Case series 17
Imatinib MDS/MPD Case series 16
Imatinib DFSP Case series 12
Imatinib HES-CEL Case series 11
ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocytosis; CML, chronic myeloid leukemia; CRC, colorectal cancer; DMSP,
dermatoﬁbrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hypereosinophilic syndrome-chronic eosinophilic leukemia; LYG, life-year
gained; PBAC, Pharmaceutical Beneﬁts Advisory Committee; MDS/MPD, myelodysplastic/myeloproliferative diseases; sALCL, systemic
anaplastic large cell lymphoma.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 6 C ( 2 0 1 5 ) 1 4 3 – 1 4 9146alternative treatment, severe and life-threatening condition, very
small number of patients, and provides substantial beneﬁts [17].
The uncertainty inherent in conducting economic modeling on
such limited clinical data, however, was frequently highlighted by
the PBAC, such that it is likely that discounts will have been
necessary to offset this uncertainty. Risk-sharing schemes can also
be potentially used to address this, as recommended by the PBAC
in its appraisal of imatinib in acute lymphoblastic leukemia.
In addition to the two submissions rejected, and the two
indications receiving restricted approval, ﬁve of the six indica-
tions that received full PBAC approval without restrictions were
rejected in their initial submission (all except brentuximab),
receiving approval only upon resubmission (Table 4). In seven
of the nine submissions that were rejected or restricted, a lack of
suitable clinical data was cited as a key explanation, with
incremental cost-effectiveness ratios recognized as being unac-
ceptably high and uncertain in four of these (Table 4). That
insufﬁcient clinical data was a key reason for many drugs beingTable 3 – Key economic evaluation outcome data of onco
trial data package lacking comparative phase III data.
Drug Indication PBAC-
nominated
comparator?
PBAC-accepte
o15 15–45 45–75
Imatinib DFSP ✓ ✓
Imatinib First- line
ALL
✓ ✓
Imatinib HES-CEL ✓ ✓
Imatinib MDS/MPD ✓ ✓
Imatinib ASM ✓ ✓
Brentuximab sALCL ✓ ✓
Dasatinib ALL ✓
Imatinib Second-
line ALL
✓
Cetuximab CRC ✓
Bevacizumab GBM ✓
Nilotinib CML ✓ NA—co
ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocyt
dermatoﬁbrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hyper
mental cost-effectiveness ratio; LYG, life-year gained; MDS/MPD, myelo
PBAC, Pharmaceutical Beneﬁts Advisory Committee; QALY, quality-adjurejected or restricted indicates that the PBAC in addition to
needing to ﬁnd the therapy to be cost-effective is more demand-
ing of survival data, greater patient numbers, and trial compara-
bility to grant approval on this basis compared with the TGA.Conclusions
Oncologic submissions that lack supportive phase III comparative
data can attain TGA regulatory approval in Australia if they meet
the following requirements (as outlined in the EMA guidelines on
the Evaluation of Anticancer Medicinal Products in Man [EMEA/
EWP/205/95] [18], adopted by the TGA):1.log
d IC
7
st
osis
eos
dys
stedEvidence for efﬁcacy is convincing and either the
2. Condition is rare or
3. The condition is a life-threatening one for which no other
therapy is available.ics appraised by the PBAC on the basis of a pivotal
ER (AU $, 000) Metric
(cost
per…)
Rule
of
rescue
Decision
5–105 105–200 4200
Responder ✗ ✓
LYG ✗ ✓
Responder ✗ ✓
Responder ✗ ✓
Responder ✗ ✓
QALY ✗ ✓
✓ LYG ✓ ✓
✓ LYG ✗ ✗
✓ QALY ✗ ✗
✓ QALY ✗ ✗
minimization approach ✗ Restricted
; CML, chronic myeloid leukemia; CRC, colorectal cancer; DFSP,
inophilic syndrome-chronic eosinophilic leukemia; ICER, incre-
plastic/myeloproliferative diseases; NA, not available/applicable;
life-year; sALCL, systemic anaplastic large cell lymphoma.
Table 4 – Key rationale for rejections and restrictions of oncologics appraised by the PBAC on the basis of a
pivotal trial data package lacking comparative phase III data.
Drug Indication Decision Key rationale for rejection/restriction
Bevacizumab GBM ✗  Signiﬁcant intertrial comparability issues—uncertain clinical beneﬁt
 Unacceptably high ICER
Nilotinib CML— 2L/
3L
✗ 2L accelerated
phase and 3L
 Insufﬁcient clinical data in accelerated phase or 3L
✓ 2L chronic phase
Imatinib DFSP ✗ First submission  Very weak evidence (ﬁrst submission)
 Resubmission provided additional case series dataImatinib HES-CEL
Imatinib MDS/MPD
✓ Resubmission
Imatinib ASM
Dasatinib ALL ✗ First submission  Lack of any data on disease progression or survival (included in a further trial
readout in the resubmission)
 Rule of rescue did not apply in ﬁrst submission (but did in resubmission)
✓ Resubmission
Imatinib ALL— 1L/
2L
✗ 2L  ICER acceptable in 1L but not in 2L
 Optimum treatment duration uncertain —RSA recommended to address✓ 1L
Cetuximab CRC ✗  Proposed continuation rule not enforceable
 Uncertain clinical beneﬁt
 Unacceptably high ICER
Brentuximab sALCL ✗ Submitted price  The PBAC deemed that the most plausible ICER at the submitted price was too
high and uncertain
 The PBAC considered cost-effective at a reduced price that produced an ICER of
$45,000–$75,000/QALY
✓ Revised price
1L, ﬁrst line; 2L, second line; 3L, third line; ALL, acute lymphoblastic leukemia; ASM, aggressive systemic mastocytosis; CML, chronic myeloid
leukemia; CRC, colorectal cancer; DFSP, dermatoﬁbrosarcoma protuberans; GBM, glioblastoma; HES-CEL, hypereosinophilic syndrome-chronic
eosinophilic leukemia; ICER, incremental cost-effectiveness ratio; PBAC, Pharmaceutical Beneﬁts Advisory Committee; MDS/MPD, myelodysplastic/
myeloproliferative diseases; QALY, quality-adjusted life-year; RSA, risk-sharing agreement; sALCL, systemic anaplastic large cell lymphoma.
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can further support PBAC approval and public reimbursement if it
also meets both the following conditions:1. Can demonstrate satisfactory cost-effectiveness using accept-
able cost-beneﬁt metrics and2. Contains more rigorous and substantial clinical data indicat-
ing dramatic beneﬁts over the relevant comparators than was
necessary for regulatory approval
The primary limitation to this analysis and the conclusions is
that it is based on a small sample size (7 TGA-appraised
indications and 10 PBAC-appraised indications). Thus, there
may be additional/alternative circumstances, outside that which
we have observed, in which the TGA and/or the PBAC will
approve oncologics on such a limited data package. Nevertheless,
the evidence presented here illustrates that the TGA has provided
regulatory approval to oncologics that lack supportive phase III
data through “side-by-side” uncontrolled, indirect comparisons
to historical controls and/or other trial data. To offset uncertainty
in making clinical claims on such limited trial data, however, the
numerical differences need to be substantial, including in sur-
vival metrics, because the overall response rate is not endorsed
as a primary end point in the TGA-adopted EMA guidelines on
anticancer medicines. Despite the TGA having adopted the EMA
guidance on evaluating anticancer medicines, there is evidence
that the TGA uses a more rigid and stricter interpretation of the
need for a phase III trial than does the EMA and also the FDA.
This is illustrated through crizotinib, which was approved by the
FDA under the accelerated-approval program on the basis of a
pivotal phase II data in August 2011 and was approved by the
EMA in July 2012 on the basis of pivotal phase II data with topline
supportive phase III data, conditional on full phase III data being
presented when available. In contrast, the TGA, which was
presented with substantially the same data package as theEMA, rejected crizotinib until the interim study report of a
comparative phase III study was made available in August 2013
[19]. The TGA explained that under the EMA-adopted guidelines,
if crizotinib did have a “dramatic” beneﬁt, then prospective
conﬁrmation in randomized, reference-controlled studies would
be not only unnecessary but also unacceptable. Crizotinib, how-
ever, was undergoing several phase III studies versus standard
chemotherapies in this clinical setting at that time [19].
Although the TGA continues to lack an expedited or early
review program for regulatory approval of promising therapies
that treat severe diseases with few treatment options, in Europe
and America there have been recent new regulatory initiatives on
top of those already in place to enable even earlier patient access
to such therapies, namely, breakthrough therapy status by the
FDA and adaptive licensing by the EMA [3,9]. This is occurring in
tandem with a group of potentially transformational immunoon-
cology therapies coming to market, which has started with the
anti–programmed death-1/ligand agents. These agents have
demonstrated the potential to show long-term survival in a broad
range of advanced metastatic cancers. One such agent, nivolu-
mab, has shown 1-, 2-, and 3-year survival rates of 84%, 48%, and
41%, respectively, in an advanced metastatic melanoma in a
phase I trial [20]. Another agent, pembrolizumab, has already
been licensed by the FDA under the breakthrough therapy status
on the basis of a phase I trial [8]. Furthermore, in addition to
several anti–programmed death-1/ligand agents in the pipeline,
there are multiple combination products in development that
promise even more impressive survival beneﬁts. For example,
nivolumab in combination with ipilimumab has demonstrated 1-
and 2-year survival rates of 94% and 88%, respectively, in an
advanced pretreated melanoma population in a phase I trial [21].
Thus, the advent of a multitude of potentially transformational
oncology pipeline therapies alongside the addition of new chan-
nels for early EMA and FDA regulatory approval will undoubtedly
increase the number of oncology therapies that will receive
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comparative phase III data by these bodies. Thus, without an
expedited regulatory approval process for market access, Aus-
tralian patients run the risk of experiencing substantial delays in
receiving innovative new therapies, compared with their Euro-
pean and American counterparts. Australia would be wise to
explore expedited access programs similar to the ones in the
United States and the European Union to enable more rapid
patient access for promising pipeline agents that treat life-
threatening diseases that lack efﬁcacious alternatives.
Caution must be exercised over exactly how such an expe-
dited regulatory program is set up, particularly in the context that
failure rates in phase III trials are more than 50% in oncology [22].
Thus, approving drugs on an early-stage data package before the
publication of phase III data could risk exposing patients to drugs
that lack clinical beneﬁts or cause harm. Indeed, only 21 of 55
oncology indications approved under the FDA accelerated-
approval pathway have presented conﬁrmatory mature trial data
and been converted to regular approval despite some being on
the market for up to 9 years [23]. Furthermore, 10% (3 of 30) of the
drugs that have conducted conﬁrmatory trials have been sub-
sequently withdrawn because of efﬁcacy and/or safety concerns.
This suggests that in the absence of conﬁrmatory data submis-
sion being a strict, nonnegotiable requirement with a deﬁned
time limit, the FDA accelerated-approval pathway has and may
continue to allow access to unsafe or inefﬁcacious therapies.
Nevertheless, even if the TGA were to implement an expe-
dited early access approval program, there are often substantial
delays and sometimes insurmountable barriers to overcome
between TGA approval and the PBAC issuing a positive recom-
mendation, necessary for PBS listing and public reimbursement.
Eighty percent of PBAC recommendations between 2005 and 2011
required multiple submissions before receiving approval [10].
Such delays in attaining reimbursement may be increasing, with
the average time between TGA approval and PBS listing of cancer
medicines growing from 14.6 months in 2003 to 31.0 months in
2013 [11]. For example, a particular key focus in Australia is
melanoma, as the country with the greatest global age-
standardized incidence rates [12]. Several recent key therapeutic
advances in this disease have faced signiﬁcant delays to public
reimbursement in Australia. Ipilimumab was listed on the PBS
only in August 2013 after three PBAC submissions [24], despite
being approved by the pan-Canadian Oncology Drug Review in
May 2012 [25], the National Institute for Health and Care Excel-
lence (NICE) in December 2012 [26], and the Scottish Medicines
Consortium (SMC) in April 2013 [27]. Furthermore, vemurafenib
has never been listed on the PBS, not receiving PBAC approval in
two submissions [28], despite being approved by the pan-
Canadian Oncology Drug Review in June 2012 [29], NICE in
December 2012 [30], and the SMC in December 2013 [31]. The
increasing number of oncologics with companion biomarker
diagnostic tests adds yet another source of delay to gaining
reimbursement in Australia. This is because such tests must be
approved by the Medical Services Advisory Committee (MSAC)
and listed on the Medicare Beneﬁts Scheme before PBS listing of
the respective oncologic. MSAC appraisals are complex, and
failure to meet its requirements can result in substantial delays
to patient access. This is illustrated by crizotinib, a ﬁrst-in-class
oncologic targeting the 4% to 7% of the patients with non–small
cell lung carcinoma with an ALKþ mutation. In addition to the
delays in achieving TGA regulatory approval (detailed above), the
PBAC deferred the crizotinib submission in November 2013 and
again in March 2014 with the failure of the MSAC to recommend
the ALK-mutation diagnostic test cited as key [32]. As of October
2014, crizotinib is yet to be approved by the PBAC or the MSAC,
despite having already been approved by other key HTA bodies,
including the Swedish Dental and Pharmaceutical BeneﬁtsAgency (TLV, February 2014) [33], the pan-Canadian Oncology
Drug Review (May 2013) [34], and the SMC (October 2013).
Previous research has demonstrated that principally the same
reduced data package used to gain EMA approval has been
sufﬁcient to gain favorable pricing and reimbursement by key
European HTA bodies [6]. The Transparency Commission (France)
fully reimbursed 14 of 14 (100%) such oncologics, with 10 of 14
obtaining Improvement of Medical Beneﬁt (Amelioration du
Service Medical Rendu - ASMR) assessments of I to III. Six of 6
(100%) oncologics appraised by the Federal Joint Commission
(Gemeinsame Bundesausschuss - G-BA, Germany) were deemed
to offer some added beneﬁt, avoiding reference pricing, with NICE
approving 5 of 8 (63%), the SMC 6 of 11 (55%), and the TLV 7 of 7
(100%). At ﬁrst glance, the PBAC approving eight such indications
seems favorable in comparison to major European obligatory
cost-utility HTA bodies. Four PBAC-approved indications, how-
ever, comprised a single submission for four rare indications of
imatinib, which no other European HTA body (except the Trans-
parency Commission) appraised. Furthermore, all the drugs
approved by the PBAC on a data package lacking comparative
phase III data except one were approved in either 2007 or 2008.
Indeed, since the end of 2008, only two drugs have been
appraised by the PBAC on such a data package, only one of
which was approved.
TGA-approved drugs that are not listed on the PBS are
available to Australian patients only through the private sector.
Given the extremely high cost of many of these agents (ipilimu-
mab [Yervoy], cost 4AU $100,000 per patient before PBS subsi-
dization), this is not a realistic avenue for widespread patient
access. Drugs lacking TGA approval can be accessed by patients
through the Special Access Scheme [35]. This is a TGA-
administered program through which patients with severe dis-
eases and no treatment alternatives can access drugs before
regulatory approval. Approval is granted on a named-patient
basis, and any prescription issued under this scheme is treated as
a private prescription. Thus, such programs are at a substantial
cost to the sponsor and/or the participating institutions. This
provides temporary access until a drug is licensed and reim-
bursed; companies may withdraw such arrangements if the
medicine does not achieve PBAC approval. Indeed, crizotinib,
which is yet to receive PBS approval, had its Special Access
Scheme terminated in June 2014. Interestingly, the UK medicines
regulatory body, the Medicines and Healthcare Products Regula-
tory Agency, announced in April 2014 an Early Access to Medi-
cines Scheme for unlicensed therapies that would be on a cohort
patient basis and would be linked to a newly introduced coordi-
nated NICE technology appraisal and National Health Service
England commissioning process [36], perhaps providing a model
by which highly innovative therapies for severe diseases with few
treatment options could gain access for Australian patients.
In summary, we have shown that despite lacking an expe-
dited regulatory approval pathway for severe diseases that lack
efﬁcacious alternatives, the TGA can approve and the PBAC will
reimburse drugs on the basis of data packages lacking compara-
tive phase III data. The expansion of early access programs by the
EMA and the FDA coupled with the lack of such an alternative for
the TGA and continued delays to achieving PBAC reimbursement,
however, may mean that Australian patients may continue to
experience delays in access and that these will become further
exaggerated over time. We recommend that Australia explore the
ideas of Europe and the United States in expedited access
programs and adaptive licensing to ensure that Australia patients
with life-threatening diseases with no efﬁcacious treatment
options can receive timely access to promising therapies. To
avoid the potential weaknesses of such an approach, mandatory
comparative data collection should be considered alongside this.
In addition, to speed up access to new drugs, it may be advisable
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simplifying the process of approval for diagnostic tests.
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